Hartford HealthCare Cancer Institute introduces new Director of Breast Surgery

Cara Livernois | | Health Exec | Management

The Hartford (Conn.) HealthCare Cancer Institute has announced their new director of the breast surgery program as Edward Sauter, MD, PhD, reports Fox61.

Coming from the University of Texas Health Science Center, Sauter has been practicing for 25 years, conducted 70 clinical research trials and referred more than 4,000 women to active clinical trials. He will lead the breast surgery programs at Hartford’s five cancer centers and aims to create resources for patients and their families.

"Incidents, the number of cases, is going up both in the U.S. and worldwide, the number of deaths from breast cancer is not," Sauter said. "It's preventing the disease, earlier detection and better treatment."

""
Cara Livernois, News Writer

Cara joined TriMed Media in 2016 and is currently a Senior Writer for Clinical Innovation & Technology. Originating from Detroit, Michigan, she holds a Bachelors in Health Communications from Grand Valley State University.

Related Content

Q&A: Proposed changes to Social Security Act would recognize pharmacists as healthcare providers
FDA issues Class I recall on counterfeit infusion pump batteries
FDA issues alert on PCNL sheath safety after patient death
Bipartisan bills in Congress would force insurance companies, PBMs to sell pharmacies
Anthem BCBS reverses course on anesthesia time limits
FDA issues Class I recall on insulin syringes due to risk of death

Around the web

Cardiovascular Business
FDA says years-long tirzepatide shortage is resolved, will give limited leeway to compounders

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

AI in Healthcare
From Capitol Hill to a hospital near you? 5 federal recommendations for healthcare AI policy

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Cardiovascular Business
Merck spends up to $2B to license new weight loss drug with potential heart benefits

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.